NBP Suppresses Astrocyte Proliferation Following CCH
We performed double immunofluorescence labeling of GFAP and BrdU to detect astrocyte regeneration. Compared to rats in the sham group, CCH rats showed an increased number of GFAP+/BrdU+ double-positive cells at 2 weeks (P < 0.05) and 4 weeks (P < 0.001). Treatment with NBP reduced astrocyte regeneration at 2 weeks (P < 0.01 NBP60 vs. model group; P < 0.001 NBP120 vs. model group) and 4 weeks (all P < 0.001, NBP60 or NBP120 vs. model group; Figures 5A,B).
Figure 5  Dl-3-n-butylphthalide (NBP) suppresses astrocytes regeneration after 2VO. (A) Representative images of GFAP (red) and BrdU (green) immunofluorescence double labeling in corpus callosum at 2 weeks and 4 weeks after 2VO. Bar = 50 μm. Typical double-labeled areas are magnified (n = 3 in each group). (B) The number of GFAP+/BrdU+ cells in corpus callosum. *p < 0.05, ***p < 0.001, the model group vs. the sham group; ##p < 0.01, ###p < 0.001, the NBP60 group or NBP120 group vs. the model group; $$p < 0.01, the NBP60 group vs. NBP120 group; &&&p < 0.001, the model group sacrificed at 2 weeks vs. the model group sacrificed at 4 weeks. Values are expressed as mean ± SD. GFAP, glial fibrillary acidic protein.